ANGIOTAX
A small French trial showed weekly paclitaxel controls angiosarcoma in most patients for a few months, making it the standard drug for this rare vascular cancer.
Overview
ANGIOTAX was a single-arm phase 2 trial of the French Sarcoma Group in which 30 patients with unresectable or metastatic angiosarcoma received weekly paclitaxel 80 mg/m2. Most patients were free of progression at two months, the primary endpoint, with responses concentrated in cutaneous scalp and face angiosarcoma, and toxicity was mild. Published in the Journal of Clinical Oncology in 2008, it made weekly paclitaxel the reference systemic treatment for angiosarcoma; the successor ANGIOTAX-PLUS trial found that adding bevacizumab did not improve outcomes.
Similar pages
not linked directly; found by shared links- CancerEpithelioid haemangioendothelioma
Shares Angiosarcoma, Vascular tumours (angiosarcoma, epithelioid haemangioendothelioma, kaposiform haemangioendothelioma), Paclitaxel / nab-paclitaxel and the tag subtype-page.
- CancerAdult granulosa cell tumour of the ovary
Shares Paclitaxel / nab-paclitaxel and the tag subtype-page.
- CancerClear cell ovarian cancer
Shares Paclitaxel / nab-paclitaxel and the tag subtype-page.
- TrialENLIVEN
Shares Sarcomas (soft tissue, bone, GIST) and the tag subtype-page.
- TrialAMPECT
Shares Sarcomas (soft tissue, bone, GIST) and the tag subtype-page.
- CancerLow-grade serous ovarian cancer
Shares Paclitaxel / nab-paclitaxel and the tag subtype-page.
- TrialSTRASS (EORTC 62092)
Shares Sarcomas (soft tissue, bone, GIST) and the tag subtype-page.
- TrialEORTC 62012
Shares Sarcomas (soft tissue, bone, GIST) and the tag subtype-page.